Lukas Biomedical Inc.
Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distribute… Read more
Lukas Biomedical Inc. (6814) - Total Assets
Latest total assets as of June 2025: NT$452.48 Million TWD
Based on the latest financial reports, Lukas Biomedical Inc. (6814) holds total assets worth NT$452.48 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lukas Biomedical Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Lukas Biomedical Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lukas Biomedical Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Lukas Biomedical Inc.'s total assets of NT$452.48 Million consist of 26.1% current assets and 73.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 13.6% |
| Accounts Receivable | NT$9.68 Million | 2.0% |
| Inventory | NT$38.02 Million | 8.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Lukas Biomedical Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lukas Biomedical Inc.'s current assets represent 26.1% of total assets in 2024, an increase from 13.6% in 2019.
- Cash Position: Cash and equivalents constituted 13.6% of total assets in 2024, up from 7.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 8.0% of total assets.
Lukas Biomedical Inc. Competitors by Total Assets
Key competitors of Lukas Biomedical Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lukas Biomedical Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lukas Biomedical Inc. generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lukas Biomedical Inc. is currently not profitable relative to its asset base.
Lukas Biomedical Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 2.19 | 0.77 |
| Quick Ratio | 0.74 | 1.86 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$18.60 Million | NT$ 128.01 Million | NT$ -22.79 Million |
Lukas Biomedical Inc. - Advanced Valuation Insights
This section examines the relationship between Lukas Biomedical Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.45 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 8.0% |
| Total Assets | NT$476.50 Million |
| Market Capitalization | $10.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lukas Biomedical Inc.'s assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Lukas Biomedical Inc.'s assets grew by 8.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Lukas Biomedical Inc. (2019–2024)
The table below shows the annual total assets of Lukas Biomedical Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$476.50 Million | +8.00% |
| 2023-12-31 | NT$441.19 Million | -8.02% |
| 2022-12-31 | NT$479.67 Million | -9.71% |
| 2021-12-31 | NT$531.24 Million | +1.46% |
| 2020-12-31 | NT$523.61 Million | -5.85% |
| 2019-12-31 | NT$556.12 Million | -- |